-- Datang International Power Generation's (HKG:0991, SHA:601991) on-grid power generation in the first quarter rose 3.5% year on year to 62.4 billion kilowatt hours, according to a Hong Kong bourse on Wednesday.
The Chinese power company's Shanghai shares rose 1% during Thursday's afternoon trade.
All power categories posted a year-on-year increase in on-grid power generation, with gas-fired power seeing the biggest growth with a 22% year-on-year jump to 5.07 billion kWh.
American Tungsten & Antimony (ASX:AT4) has joined the US Defense Industrial Base Consortium (DIBC), gaining access to US defense programs and advancing its antimony and tungsten strategy amid a growing focus on secure domestic critical mineral supply chains, according to a Friday Australian bourse filing.The company, through the consortium, gains access to Department of War programs, funding opportunities, and defense partnerships to advance domestic processing and strengthen supply chains in line with national security priorities, per the filing.The company also stated that over 50 DIBC-related projects have already secured about $410 million in funding, including roughly $39 million this year, highlighting strong government support, the filing said.The company will host a government-level critical minerals event in Utah on May 15, bringing together senior US officials, state leaders, and industry stakeholders, the filing added.The company's shares rose 12% in recent Friday trade.
EBR Systems (ASX:EBR) received priority review determination from the Therapeutic Goods Administration for the WiSE System, according to a Friday filing with the Australian bourse.The WiSE System is a cardiac device capable of pacing the heart without a lead.The determination provides an accelerated pathway for the device to be included on the Australian Register of Therapeutic Goods, the filing said.Shares rose 7% in morning trade on Friday.
Star Sports Medicine (HKG:1609) launched its Hong Kong initial public offering on Friday, seeking to raise about HK$829.6 million from the deal.The China-based medical device company is offering 8.4 million H-shares at an offer price of HK$98.50 per share, according to a Hong Kong bourse filing.The offering comprises 842,200 shares for Hong Kong investors and 7.6 million shares for international investors, subject to reallocation.The Hong Kong public offering closes on April 29, with allocation results due by May 4, ahead of the company's planned trading debut on May 5.Net proceeds will be used mainly to expand production capacity and enhance manufacturing efficiency, as well as support research and development.The funds will also be used to strengthen sales and marketing capabilities, expand global distribution, and for working capital and general corporate purposes.CITIC Securities (Hong Kong) and CCB International Capital are acting as joint sponsors.CLSA and CCB International Capital are serving as overall coordinators, alongside China Galaxy International Securities and CMBC Securities, and are also acting as joint bookrunners.Futu Securities International (Hong Kong), Open Securities, Orient Securities (Hong Kong), and Zheshang International Financial are acting as joint bookrunners and joint lead managers.